APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)

To describe patients' compliance of taking Aromatase Inhibitor as an adjuvant treatment in the postmenopausal, early breast cancer as seen under current practice

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Behavior Breast Diseases Breast Neoplasms Health Behavior Neoplasms Neoplasms by Site Patient Acceptance of Health Care Patient Compliance Skin Diseases Skin and Connective Tissue Diseases Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Research Site, Cheonan-si, Chuncheongnam-do, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Provision of written informed consent
Patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice
Histologically or cytologically proven to be HR+(ER or PR +)
Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline):

Age >= 50 years
Age < 50 years with amenorrhoea > 12 months and an intact uterus
FSH levels within postmenopausal range (over 30-40 IU/ml), or
Having undergone a bilateral oophorectomy.
No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators

Exclusion criteria

Recurrence of breast cancer
Known hypersensitivity to aromatase inhibitor or to any of the excipients
Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol
Previous inclusion in the present study
Participation in a clinical study during the last 30 days

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer

Acronym: APOLLO

Important dates

Study start: 2007
Primary completion: 2011
Study completion: 2011
First posted: Aug 31, 2007
Registry last updated: May 20, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed